{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:23:52Z","timestamp":1789129432177,"version":"build-2803163510"},"reference-count":33,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100010648","name":"Universitaire Ziekenhuizen Leuven, KU Leuven","doi-asserted-by":"publisher","award":["KAC2M\/25\/047"],"award-info":[{"award-number":["KAC2M\/25\/047"]}],"id":[{"id":"10.13039\/501100010648","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Internal Funds (C2) KU Leuven"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Rare Disease"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Rare diseases collectively affect approximately 6% of the global population, yet 95% of affected individuals lack access to effective treatments. Beyond this persistent therapeutic gap, patients and caregivers face a broad spectrum of unmet needs, spanning psychosocial challenges, access to reliable diagnostic information, care coordination, and long-term follow-up, which remain poorly characterised in both clinical and policy contexts. Three interrelated challenges underpin this problem. First, validated instruments capable of systematically capturing unmet needs across diverse patient groups, including adults, minors, and caregivers, are largely absent. Second, even when patient data are collected, they are rarely integrated into clinical trial design, regulatory evaluation, or reimbursement deliberations in a structured and reproducible manner. Third, the responsible governance of rare disease data, particularly across institutional and national boundaries, faces unresolved ethical, legal, and organisational barriers. This perspective paper outlines the conceptual foundations of the INFORM-RD research project (a patient-informed clinical platform to inform patient-centred decision-making for rare diseases), embedded at KU Leuven, Leuven Institute for Rare Diseases and University Hospitals Leuven, Belgium. Drawing on the KCE NEED framework and leveraging a cohort of over 30,000 people with rare diseases, INFORM-RD aims to: 1) develop and validate a scalable methodology for unmet need data collection, 2) translate these data into actionable decision-support tools for clinicians, regulators, and payers, and 3) establish an ethical and legal governance architecture enabling responsible and scalable data sharing at national and international levels. By positioning patients, including underrepresented groups such as children and persons with cognitive limitations, as co-creators throughout the research process, INFORM-RD offers a transferable blueprint for need-driven rare disease care across Europe.<\/jats:p>","DOI":"10.1177\/26330040261486869","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:28:40Z","timestamp":1788802120000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Addressing unmet needs in rare diseases: A patient-centred vision through INFORM-RD"],"prefix":"10.1177","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0146-0087","authenticated-orcid":false,"given":"Kenji","family":"Demesure","sequence":"first","affiliation":[{"name":"KU Leuven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien","family":"Beckers","sequence":"additional","affiliation":[{"name":"KU Leuven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Vansteenkiste","sequence":"additional","affiliation":[{"name":"P.H. Belgi\u00eb VZW - Belgische Pati\u00ebntenvereniging voor Pulmonale Hypertensie"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8802-663X","authenticated-orcid":false,"given":"Ruxanda","family":"Berlinschi","sequence":"additional","affiliation":[{"name":"KU Leuven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Blonda","sequence":"additional","affiliation":[{"name":"KU Leuven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Dobbels","sequence":"additional","affiliation":[{"name":"KU Leuven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elja","family":"Eskes","sequence":"additional","affiliation":[{"name":"University Hospitals Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Delcroix","sequence":"additional","affiliation":[{"name":"KU Leuven"},{"name":"University Hospitals of Leuven, Leuven, Belgium"},{"name":"KU Leuven"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Huys","sequence":"additional","affiliation":[{"name":"KU Leuven"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00180-y"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-019-0508-0"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.315"},{"key":"e_1_3_7_5_2","volume-title":"EUR-Lex","author":"Regulation - 141\/2000 - EN","year":"2000","unstructured":"Regulation - 141\/2000 - EN. EUR-Lex, 2000. https:\/\/eur-lex.europa.eu\/eli\/reg\/2000\/141\/oj\/eng accessed 27 March 2026."},{"key":"e_1_3_7_6_2","article-title":"Juggling care and daily life, The balancing act of the rare disease community, A Rare Barometer survey","author":"Courbier S","year":"2017","unstructured":"Courbier S, Berjonneau E. Juggling care and daily life, The balancing act of the rare disease community, A Rare Barometer survey. EURORDIS 2017. https:\/\/www.eurordis.org\/ accessed 27 March 2026.","journal-title":"EURORDIS"},{"key":"e_1_3_7_7_2","volume-title":"Shifting towards needs-driven healthcare","author":"KCE","year":"2024","unstructured":"KCE. Shifting towards needs-driven healthcare. KCE Reports, 2024. https:\/\/kce.fgov.be\/en\/about-us\/press-release\/shifting-towards-needs-driven-healthcare-highlights-from-the-belgian-high-level-conference accessed 27 March 2026."},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03838-6"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/hex.12640"},{"key":"e_1_3_7_10_2","first-page":"1","volume-title":"Pharmaceutical Strategy for Europe","author":"European Commission","year":"2020","unstructured":"European Commission. Pharmaceutical Strategy for Europe. Communication from the Commission to the European parliament, the Council, the European Economic and Social Committee and the Committee of the Regions, 2020, pp. 1\u201316."},{"key":"e_1_3_7_11_2","unstructured":"Levy M Swartenbroekx N Gerkens S. Identification evaluation and selection of health conditions for the NEED Research Programme 2020. https:\/\/www.kce.fgov.be\/ accessed 27 March 2026."},{"key":"e_1_3_7_12_2","volume-title":"PRIME: priority medicines","author":"European Medicines Agency (EMA)","year":"2016","unstructured":"European Medicines Agency (EMA). PRIME: priority medicines, 2016. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/prime-priority-medicines accessed 27 March 2026."},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.902150"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0718-x"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_302"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.12.018"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0810-x"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2025.100570"},{"key":"e_1_3_7_19_2","doi-asserted-by":"crossref","unstructured":"Claessens Z Vanneste A Broekmans J et al. Needs Examination Evaluation and Dissemination (NEED): Applicability to Rare Diseases. https:\/\/www.kce.fgov.be\/ (2024) accessed 27 March 2026.","DOI":"10.57598\/R377C4"},{"key":"e_1_3_7_20_2","unstructured":"Emilie N Arianna G Adam H. Addressing unmet needs in extremely rare and paediatric-onset diseases: how the biopharmaceutical innovation model can help identify current issues and find potential solutions (2021). https:\/\/www.dolon.com\/ accessed 27 March 2026."},{"key":"e_1_3_7_21_2","unstructured":"Regulation (EU) 2021\/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011\/24\/EU (Text with EEA relevance) - EN. EUR-Lex 2026. https:\/\/eur-lex.europa.eu\/eli\/reg\/2021\/2282\/oj\/eng accessed 29 March 2026."},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03095-z"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0297832"},{"key":"e_1_3_7_24_2","volume-title":"Guidance on parallel EMA\/EUnetHTA 21 Joint Scientific Consultation","author":"European Medicines Agency","year":"2022","unstructured":"European Medicines Agency. Guidance on parallel EMA\/EUnetHTA 21 Joint Scientific Consultation, 2022. https:\/\/www.eunethta.eu\/, accessed 27 March 2026."},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.07.007"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1074512"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/11635320-000000000-00000"},{"key":"e_1_3_7_28_2","volume-title":"European Health Data Space Regulation (EU) 2025\/327 - EN","year":"2025","unstructured":"European Health Data Space Regulation (EU) 2025\/327 - EN. EUR-Lex. Official Journal of the European Union, 2025. https:\/\/eur-lex.europa.eu\/eli\/reg\/2025\/327\/oj\/eng, accessed 27 March 2026."},{"key":"e_1_3_7_29_2","volume-title":"European Reference Networks","author":"European Commission","year":"2024","unstructured":"European Commission. European Reference Networks. Public Health - European Commission, 2024. https:\/\/health.ec.europa.eu\/rare-diseases-and-european-reference-networks\/european-reference-networks_en accessed 27 March 2026."},{"key":"e_1_3_7_30_2","volume-title":"Integration of European Reference Networks into national healthcare systems","author":"JARDIN Joint Action","year":"2025","unstructured":"JARDIN Joint Action. Integration of European Reference Networks into national healthcare systems. JARDIN, 2025. https:\/\/jardin-ern.eu\/ accessed 27 March 2026."},{"key":"e_1_3_7_31_2","volume-title":"New EU rules for health technology assessments become effective","year":"2026","unstructured":"New EU rules for health technology assessments become effective. European Medicines Agency (EMA), 2026. https:\/\/www.ema.europa.eu\/en\/news\/new-eu-rules-health-technology-assessments-become-effective accessed 29 March 2026."},{"key":"e_1_3_7_32_2","volume-title":"EU rare disease action plan","author":"European Parliament Research Service","year":"2023","unstructured":"European Parliament Research Service. EU rare disease action plan. Brussels, EPRS, 2023. https:\/\/doi.org\/10.2861\/2994008"},{"key":"e_1_3_7_33_2","volume-title":"Revision of EU legislation on medicines for children and rare diseases","author":"Dolors M","year":"2023","unstructured":"Dolors M, Tiemo W. Revision of EU legislation on medicines for children and rare diseases. European Parliament legislative resolution, 2023."},{"key":"e_1_3_7_34_2","volume-title":"EJP RD \u2013 European Joint Programme on Rare Diseases","author":"European Rare Disease Research Alliance (ERDERA)","year":"2026","unstructured":"European Rare Disease Research Alliance (ERDERA). EJP RD \u2013 European Joint Programme on Rare Diseases, 2026. https:\/\/www.ejprarediseases.org\/ accessed 27 March 2026."}],"container-title":["Therapeutic Advances in Rare Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26330040261486869","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/26330040261486869","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26330040261486869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:18:47Z","timestamp":1789125527000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/26330040261486869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"alternative-id":["10.1177\/26330040261486869"],"URL":"https:\/\/doi.org\/10.1177\/26330040261486869","relation":{},"ISSN":["2633-0040","2633-0040"],"issn-type":[{"value":"2633-0040","type":"print"},{"value":"2633-0040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"article-number":"26330040261486869"}}